| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
58,625,000 |
| Market
Cap: |
1.54(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.72 - $35.59 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
93,505 |
106,505 |
124,343 |
450,780 |
| Total Sell Value |
$3,194,796 |
$3,569,126 |
$4,091,741 |
$15,155,681 |
| Total People Sold |
1 |
2 |
5 |
6 |
| Total Sell Transactions |
5 |
7 |
11 |
37 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hudson Frederick M. |
Director |
– • – |
2012-05-04 |
4 |
B |
$5.00 |
$25,000 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Nuerge William A. |
Director |
– • – |
2012-05-04 |
4 |
B |
$5.00 |
$75,000 |
D/D |
15,000 |
23,750 |
2.39 |
- |
|
| Sheffery Michael B |
Director |
– • – |
2012-05-04 |
4 |
B |
$5.00 |
$5,500,000 |
I/I |
1,100,000 |
297,815 |
2.1 |
- |
|
| Sheffery Michael B |
Director |
– • – |
2012-05-04 |
4 |
A |
$0.00 |
$0 |
I/I |
2,499,998 |
206,816 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2012-05-04 |
4 |
B |
$5.00 |
$25,000 |
D/D |
5,000 |
402,058 |
2.81 |
- |
|
| Martin Tami Tillotson |
VP of Regulatory Affairs |
• – – |
2012-05-04 |
4 |
B |
$5.00 |
$12,500 |
D/D |
2,500 |
2,500 |
2.74 |
- |
|
| Bryan Jones W. |
VP of Business DevelopmentOffi |
• – – |
2012-04-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
65,500 |
|
- |
|
| Nuerge William A. |
Director |
– • – |
2012-04-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,750 |
|
- |
|
| Khattar Jack A. |
President, CEOOfficer |
• • – |
2012-04-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,125,000 |
|
- |
|
| Khattar Jack A. |
President, CEOOfficer |
• • – |
2012-04-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
397,058 |
|
- |
|
385 Records found
|
|
Page 16 of 16 |
|
|
0.89 (3.28%) 
